Mastocytosis: pathology, genetics, and current options for therapy
…, M Födinger, R Fritsche-Polanz… - Leukemia & …, 2005 - Taylor & Francis
Mast cell disorders are defined by an abnormal accumulation of tissue mast cells (MCs) in
one or more organ systems. Symptoms in mastocytosis result from MC-derived mediators and, …
one or more organ systems. Symptoms in mastocytosis result from MC-derived mediators and, …
Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis
R Fritsche‐Polanz, JH Jordan, A Feix… - British journal of …, 2001 - Wiley Online Library
The proto‐oncogene C‐KIT encodes a tyrosine kinase receptor that is expressed on mast
cells and haematopoietic stem cells and can show somatic mutations in patients with …
cells and haematopoietic stem cells and can show somatic mutations in patients with …
[HTML][HTML] A rapid, highly sensitive and open-access SARS-CoV-2 detection assay for laboratory and home testing
…, AD Straw, R Fritsche-Polanz… - Frontiers in Molecular …, 2022 - frontiersin.org
RT-qPCR-based diagnostic tests play important roles in combating virus-caused pandemics
such as Covid-19. However, their dependence on sophisticated equipment and the …
such as Covid-19. However, their dependence on sophisticated equipment and the …
Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes
…, WR Sperr, R Fritsche-Polanz… - International archives of …, 2005 - karger.com
Background: In contrast to aggressive mastocytosis, patients with indolent systemic mastocytosis
(ISM) usually present with urticaria pigmentosa-like skin lesions. In those who lack skin …
(ISM) usually present with urticaria pigmentosa-like skin lesions. In those who lack skin …
[HTML][HTML] High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V
R Fritsche-Polanz, M Fritz, A Huber, K Sotlar… - Molecular Oncology, 2010 - Elsevier
The KIT mutation D816V is associated with autonomous growth of mast cells (MC) and is
detectable in most patients with systemic mastocytosis (SM), including cases with associated …
detectable in most patients with systemic mastocytosis (SM), including cases with associated …
[PDF][PDF] Scalable, rapid and highly sensitive isothermal detection of SARS-CoV-2 for laboratory and home testing
…, R Heinen, NA Tanner, R Fritsche-Polanz… - …, 2020 - pdfs.semanticscholar.org
Global efforts to monitor and contain the Covid-19 pandemic, caused by the beta-coronavirus
SARS-CoV-2, currently rely on RT-qPCR-based diagnostic assays. Yet their high cost, …
SARS-CoV-2, currently rely on RT-qPCR-based diagnostic assays. Yet their high cost, …
[HTML][HTML] Evaluation of five commercial SARS-CoV-2 antigen tests in a clinical setting
…, J Atamaniuk, R Fritsche-Polanz… - Journal of General …, 2022 - Springer
Background Point-of-care antigen tests (AgTs) for the detection of severe acute respiratory
syndrome coronavirus type 2 (SARS-CoV-2) enable the rapid testing of infected individuals …
syndrome coronavirus type 2 (SARS-CoV-2) enable the rapid testing of infected individuals …
Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels
A Feix, R Fritsche-Polanz, J Kletzmayr… - American journal of …, 2001 - Elsevier
The prevalence of the methionine synthase (MTR) 2756A→G polymorphism among individuals
with severely elevated total homocysteine (tHcy) plasma levels is unknown. Therefore, …
with severely elevated total homocysteine (tHcy) plasma levels is unknown. Therefore, …
A case of 'smouldering'mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val
JH Jordan, R Fritsche-Polanz, WR Sperr… - Leukemia research, 2001 - Elsevier
Mastocytosis is a term used for a group of disorders characterized by abnormal growth and
accumulation of tissue mast cells (MC) in one or more organ systems. In patients with …
accumulation of tissue mast cells (MC) in one or more organ systems. In patients with …
Erythropoietin-inducible immediate-early genes in human vascular endothelial cells.
M Födinger, R Fritsche-Polanz… - … medicine: the official …, 2000 - europepmc.org
Background Patients receiving recombinant human erythropoietin (rHuEPO) may experience
side effects arising from the vascular system. The underlying mechanisms, however, are …
side effects arising from the vascular system. The underlying mechanisms, however, are …
